Asset Details
Do you wish to reserve the book?
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer
Do you wish to request the book?
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer
2024
Overview
Glycyl-tRNA synthetase (
GARS1
) is differentially expressed across cancers. In this study, the value of GARS1 in the diagnosis and prognosis of various cancers was comprehensively evaluated by multiple omics integrative pan-cancer analysis and experimental verification. Through Kaplan–Meier, ROC and multiple databases, we explored
GARS1
expression and prognostic and diagnostic patterns across cancers. The
GARS1
relative reaction network was identified in PPI, GO, KEGG, methylation models and the genetic mutation atlas. Further research on the
GARS1
value in bladder urothelial carcinoma (BLCA) was conducted by regression and nomogram models. We further analyzed the correlation between
GARS1
and immune markers and cells in BLCA. Finally, in vitro experiments were used to validate
GARS1
the oncogenic function of
GARS1
in BLCA. We found that
GARS1
was highly expressed across cancers, especially in BLCA.
GARS1
expression was correlated with poor survival and had high diagnostic value in most tumor types.
GARS1
is significantly associated with tRNA-related pathways whose mutation sites are mainly located on tRNA synthetase. In addition, Upregulation of
GARS1
was connected with immune cell infiltration and five key MMR genes. M2 macrophages, TAMs, Th1 and T-cell exhaustion, and marker sets associated with
GARS1
expression indicated specific immune infiltration in BLCA. Finally, in vitro experiments validated that
GARS1
expression promotes BLCA cell proliferation and metastasis and inhibits apoptosis. Overall,
GARS1
can be a novel prognostic and immunological biomarker through multiple omics integrative pan-cancer analysis. The expression of
GARS1
in BLCA was positively correlated with specific immune infiltration, indicating that
GARS1
might be related to the tumor immune microenvironment.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/67
/ 692/4025
/ Biomarkers, Tumor - genetics
/ Cancer
/ Cell Proliferation - genetics
/ GARS1
/ Gene Expression Regulation, Neoplastic
/ Glycine-tRNA Ligase - immunology
/ Glycine-tRNA Ligase - metabolism
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ Science
/ tRNA
/ Tumor Microenvironment - genetics
/ Tumor Microenvironment - immunology
/ Tumors
/ Urinary Bladder Neoplasms - genetics
/ Urinary Bladder Neoplasms - immunology
/ Urinary Bladder Neoplasms - mortality
